FMP
NASDAQ
0.778 USD
-0.0026 (-0.334%)
Mr. Eric D. Shaff M.B.A.
Healthcare
Biotechnology
https://www.serestherapeutics.com
NASDAQ
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation...
0001609809
US81750R1023
81750R102
200 Sidney Street
617 945 9626
US
233
Jun 26, 2015
0001609809
NASDAQ
Biotechnology
Healthcare
81750R102
US81750R1023
US
0.78
2.27
4.68M
117.42M
-
0.732-6.87
-0.02
-
-
-
-
-0.87
-
https://www.serestherapeutics.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.